 Roche said its experimental Alzheimers treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roches Alzheimers Drug Fails In Phase 3; Heres The Fallout For Biogen, Lilly, Prothena And Others appeared first on Investors Business Daily. 